133 related articles for article (PubMed ID: 2746265)
1. The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease.
Weiner WJ; Factor SA; Sanchez-Ramos JR
J Neurol Neurosurg Psychiatry; 1989 Jun; 52(6):732-5. PubMed ID: 2746265
[TBL] [Abstract][Full Text] [Related]
2. The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results.
Coleman RJ; Lange KW; Quinn NP; Loper AE; Bondi JV; Hichens M; Stahl SM; Marsden CD
Mov Disord; 1989; 4(2):129-38. PubMed ID: 2733705
[TBL] [Abstract][Full Text] [Related]
3. MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.
Lieberman A; Chin L; Baumann G
Clin Neuropharmacol; 1988 Jun; 11(3):191-200. PubMed ID: 2900065
[TBL] [Abstract][Full Text] [Related]
4. Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa.
Ahlskog JE; Muenter MD; Bailey PA; Miller PM
Clin Neuropharmacol; 1991 Jun; 14(3):214-27. PubMed ID: 1676932
[TBL] [Abstract][Full Text] [Related]
5. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
Goetz CG; Stebbins GT; Blasucci LM
Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
[TBL] [Abstract][Full Text] [Related]
6. (+)-4-Propyl-9-hydroxynaphthoxazine in Parkinson's disease.
Grandas Perez FJ; Jenner PG; Nomoto M; Stahl S; Quinn NP; Parkes JD; Critchley P; Marsden CD
Lancet; 1986 Apr; 1(8486):906. PubMed ID: 2870368
[No Abstract] [Full Text] [Related]
7. Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation.
Cedarbaum JM; Clark M; Toy LH; Green-Parsons A
Mov Disord; 1990; 5(4):298-303. PubMed ID: 1979657
[TBL] [Abstract][Full Text] [Related]
8. Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease.
Coleman RJ; Quinn NP; Traub M; Marsden CD
J Neurol Neurosurg Psychiatry; 1990 Feb; 53(2):102-5. PubMed ID: 1968963
[TBL] [Abstract][Full Text] [Related]
9. [Treatment for advanced Parkinson's disease with intestinal levodopa/carbidopa gel: review of efficacy and safety].
Timofeeva AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):145-51. PubMed ID: 25629138
[TBL] [Abstract][Full Text] [Related]
10. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087
[TBL] [Abstract][Full Text] [Related]
11. Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa.
Frackiewicz EJ; Jhee SS; Shiovitz TM; Webster J; Topham C; Dockens RC; Whigan D; Salazar DE; Cutler NR
Ann Pharmacother; 2002 Feb; 36(2):225-30. PubMed ID: 11847938
[TBL] [Abstract][Full Text] [Related]
12. Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.
Martínez-Martín P; Hernández B; Ricart J;
Neurologia; 2014 Apr; 29(3):153-60. PubMed ID: 23465686
[TBL] [Abstract][Full Text] [Related]
13. PHNO [(+)-4-propyl-9-hydroxynaphthoxazine]: a new and effective anti-Parkinson's disease agent.
Muenter MD; Ahlskog JE; Bell G; McManis P
Neurology; 1988 Oct; 38(10):1541-5. PubMed ID: 2901697
[TBL] [Abstract][Full Text] [Related]
14. A double-blind evaluation of ciladopa in Parkinson's disease.
Weiner WJ; Factor SA; Sanchez-Ramos J; Berger J
Mov Disord; 1987; 2(3):211-7. PubMed ID: 3332914
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
Brannan T; Yahr MD
Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
[TBL] [Abstract][Full Text] [Related]
16. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
Olanow CW; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes JD; Jankovic J
Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604
[TBL] [Abstract][Full Text] [Related]
17. Clinical inquiry. Which drugs work best for early Parkinson's disease?
Jain L; Benko R; Safranek S
J Fam Pract; 2012 Feb; 61(2):106-8. PubMed ID: 22312616
[TBL] [Abstract][Full Text] [Related]
18. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Fung VS; Herawati L; Wan Y; ;
Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
[TBL] [Abstract][Full Text] [Related]
19. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC
Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
[TBL] [Abstract][Full Text] [Related]
20. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
